DMD Simcyp

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Drug Metabolism and Disposition Fast Forward
First published on June 24, 2004; DOI: 10.1124/dmd.104.000034


0090-9556/04/3209-1015-1022$20.00
DMD 32:1015-1022, 2004

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow An erratum has been published
Right arrow All Versions of this Article:
dmd.104.000034v1
32/9/1015    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Karanam, B. V.
Right arrow Articles by Vincent, S. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Karanam, B. V.
Right arrow Articles by Vincent, S. H.

IN VITRO METABOLISM OF MK-0767 [(±)-5-[(2,4-DIOXOTHIAZOLIDIN-5-YL)METHYL]-2-METHOXY-N-[[(4-TRIFLUOROMETHYL) PHENYL]METHYL]BENZAMIDE], A PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR {alpha}/{gamma} AGONIST. I. ROLE OF CYTOCHROME P450, METHYLTRANSFERASES, FLAVIN MONOOXYGENASES, AND ESTERASES

Bindhu V. Karanam, Cornelis E.C.A. Hop, David Q. Liu, Mike Wallace, Dennis Dean, Hiroya Satoh, Masakatsu Komuro, Katsuya Awano, and Stella H. Vincent

Department of Drug Metabolism, Merck Research Laboratories, Rahway, New Jersey (B.V.K., C.E.C.A.H., D.Q.L., M.W., D.D., S.H.V.) and Kyorin Pharmaceutical Co., Japan, Tokyo, Japan (H.S., M.K., K.A.)

The metabolism of MK-0767, (±)-5-[(2,4-dioxothiazolidin-5-yl)methyl]-2-methoxy-N-[[(4-trifluoromethyl) phenyl]methyl]benzamide, a thiazolidinedione (TZD)-containing peroxisome proliferator-activated receptor {alpha}/{gamma} agonist, was studied in liver microsomes and hepatocytes from humans and rat, dog, and rhesus monkey, to characterize the enzyme(s) involved in its metabolism. The major site of metabolism is the TZD ring, which underwent opening catalyzed by CYP3A4 to give the mercapto derivative, M22. Other metabolites formed in NADPH-fortified liver microsomes included the TZD-5-OH derivative (M24), also catalyzed by CYP3A4, and the O-desmethyl derivative (M28), whose formation was catalyzed by CYP2C9 and CYP2C19. Metabolite profiles from hepatocyte incubations were different from those generated with NADPH-fortified microsomal incubations. In addition to M22, M24, and M28, hepatocytes generated several S-methylated metabolites, including the methyl mercapto (M25), the methyl sulfoxide amide (M16), and the methyl sulfone amide (M20) metabolites. Addition of the methyl donor, S-adenosyl methionine, in addition to NADPH, to microsomal incubations enhanced the turnover and resulted in metabolite profiles similar to those in hepatocyte incubations. Collectively, these results indicated that methyltransferases played a major role in the metabolism of MK-0767. Using enzyme-specific inhibitors, it was concluded that microsomal thiol methyltransferases play a more important role than the cytosolic thiopurine methyltransferase. Baculovirus-expressed human flavin-containing monooxygenase 3, as well as CYP3A4, oxidized M25 to M16, whereas further oxidation of M16 to M20 was catalyzed mainly by CYP3A4. Esterases were involved in the formation of the methyl sulfone carboxylic acids, minor metabolites detected in hepatocytes.


Address correspondence to: Bindhu V. Karanam, RY 80L-109, Merck Research Laboratories, P.O. Box 2000, Rahway, NJ 07065. E-mail: bindhu_karanam{at}merck.com




This article has been cited by other articles:


Home page
Drug Metab. Dispos.Home page
C. J. Kochansky, R. K. Rippley, K. X. Yan, H. Song, M. A. Wallace, D. Dean, A. N. Jones, K. Lasseter, J. Schwartz, S. H. Vincent, et al.

Drug Metab. Dispos., September 1, 2006; 34(9): 1457 - 1461.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
B. V. Karanam, C. J. Welch, V. G. Reddy, J. Chilenski, M. Biba, and S. Vincent

Drug Metab. Dispos., October 1, 2004; 32(10): 1061 - 1068.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
V. B. G. Reddy, G. A. Doss, M. Creighton, C. J. Kochansky, S. H. Vincent, R. B. Franklin, and B. V. Karanam

Drug Metab. Dispos., October 1, 2004; 32(10): 1154 - 1161.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
D. Q. Liu, B. V. Karanam, G. A. Doss, R. R. Sidler, S. H. Vincent, and C. E.C.A. Hop

Drug Metab. Dispos., September 1, 2004; 32(9): 1023 - 1031.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2004 by the American Society for Pharmacology and Experimental Therapeutics.